Advent of Novel Phosphatidylcholine-Associated Nonsteroidal Anti-Inflammatory Drugs with Improved Gastrointestinal Safety

키워드

참고문헌 (64)

1. Scarpignato C, "Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention", Gastroenterol Clin North Am, 39, pp.433~464 (2010)
2. Watson DJ, "Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis", Arch Intern Med, 160, pp.2998~3003 (2000)
3. Lichtenberger LM, "Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury", Nat Med, 1, pp.154~158 (1995)
4. Lichtenberger LM, "The hydrophobic barrier properties of gastrointestinal mucus", Annu Rev Physiol, 57, pp.565~583 (1995)
5. Lichtenberger LM, "Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited", Pharmacol, 61, pp.631~637 (2001)
6. Lichtenberger LM, "Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa", Dig Dis Sci, 45, pp.1792~1801 (2000)
7. Barrios JM, "Role of biliary phosphatidylcholine in bile acid protection and NSAID injury of the ileal mucosa in rats", Gastroenterology, 118, pp.1179~1186 (2000)
8. Giraud MN, "Interaction of indomethacin and naproxen with gastric surface-active phospholipids: a possible mechanism for the gastric toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs)", Biochem Pharmacol, 57, pp.247~254 (1999)
9. Lichtenberger LM, "Nonsteroidal anti-inflammatory drug and phospholipid prodrugs: combination therapy with antisecretory agents in rats", Gastroenterology, 111, pp.990~995 (1996)
10. Lichtenberger LM, "Insight into NSAID-induced membrane alterations, pathogenesis and therapeutics: characterization of interaction of NSAIDs with phosphatidylcholine", Biochim Biophys Acta, 1821, pp.994~1002 (2012)
11. Kao YC, "Localization of phospholipid-rich zones in rat gastric mucosa: possible origin of a protective hydrophobic luminal lining", J Histochem Cytochem, 35, pp.1285~1298 (1987)
12. Anand BS, "Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects", Am J Gastroenterol, 94, pp.1818~1822 (1999)
13. Lanza FL, "Clinical trial: comparison of ibuprofen-phosphatidylcholine and ibuprofen on the gastrointestinal safety and analgesic efficacy in osteoarthritic patients", Aliment Pharmacol Ther, 28, pp.431~442 (2008)
14. Lichtenberger LM, "Gastroduodenal mucosal defe", Curr Opin Gastroenterol, 15, pp.463~472 (1999)
15. Kao YC, "Morphological effects of aspirin and prostaglandin on the canine gastric mucosal surface. Analysis with a phospholipid-selective cytochemical stain", Gastroenterology, 98, pp.592~606 (1990)
16. Goddard PJ, "Luminal surface hydrophobicity of canine gastric mucosa is dependent on a surface mucous gel", Gastroenterology, 98, pp.361~370 (1990)
17. Dial EJ, "Surface hydrophobicity of the gastric mucosa in the developing rat. Effects of corticosteroids, thyroxine, and prostaglandin E2", Gastroenterology, 94, pp.57~61 (1988)
18. Kao YC, "Phospholipid- and neutral lipid-containing organelles of rat gastroduodenal mucous cells. Possible origin of the hydrophobic mucosal lining", Gastroenterology, 101, pp.7~21 (1991)
19. Lichtenberger LM, "Gastric protective activity of mixtures of saturated polar and neutral lipids in rats", Gastroenterology, 99, pp.311~326 (1990)
20. Kao YC, "A method to preserve extracellular surfactant-like phospholipids on the luminal surface of rodent gastric mucosa", J Histochem Cytochem, 38, pp.427~431 (1990)
21. Ottlecz A, "Helicobacter infection and phospholipase A2 enzymes: effect of Helicobacter felis-infection on the expression and activity of sPLA2 enzymes in mouse stomach", Mol Cell Biochem, 221, pp.71~77 (2001)
22. Lichtenberger LM, "Attenuation of hydrophobic phospholipid barrier is an early event in Helicobacter felis-induced gastritis in mice", Dig Dis Sci, 44, pp.108~115 (1999)
23. Giraud MN, "Effect of omeprazole on the bioavailability of unmodified and phospholipid-complexed aspirin in rats", Aliment Pharmacol Ther, 11, pp.899~906 (1997)
24. Serna JH, "Invasive Helicobacter-like organisms in feline gastric mucosa", Helicobacter, 2, pp.40~43 (1997)
25. Lichtenberger LM, "Effect of ammonium ion on the hydrophobic and barrier properties of the gastric mucus gel layer: implications on the role of ammonium in H. pylori-induced gastritis", J Gastroenterol Hepatol, (9 Suppl 1), pp.S13~S19 (1994)
26. Ottlecz A, "Phospholipase activity of Helicobacter pylori and its inhibition by bismuth salts. Biochemical and biophysical studies", Dig Dis Sci, 38, pp.2071~2080 (1993)
27. Go MF, "Gastric mucosal hydrophobicity and Helicobacter pylori: response to antimicrobial therapy", Am J Gastroenterol, 88, pp.1362~1365 (1993)
28. Dial EJ, "A direct role for secretory phospholipase A2 and lysophosphatidylcholine in the mediation of LPS-induced gastric injury", Shock, 33, pp.634~638 (2010)
29. Dial EJ, "Oral phosphatidylcholine preserves the gastrointestinal mucosal barrier during LPS-induced inflammation", Shock, 30, pp.729~733 (2008)
30. Zayat M, "Pathophysiology of LPS-induced gastrointestinal injury in the rat: role of secretory phospholipase A2", Shock, 30, pp.206~211 (2008)
31. Dial EJ, "Lipopolysaccharide-induced gastrointestinal injury in rats: role of surface hydrophobicity and bile salts", Shock, 17, pp.77~80 (2002)
32. Dial EJ, "Role of phosphatidylcholine saturation in preventing bile salt toxicity to gastrointestinal epithelia and membranes", J Gastroenterol Hepatol, 23, pp.430~436 (2008)
33. Schmitz MG, "Phospholipids from rat, human, and canine gastric mucosa. Composition and metabolism of molecular classes of phosphatidylcholine", Gastroenterology, 99, pp.1292~1296 (1990)
34. Zhou Y, "The role of membrane cholesterol in determining bile acid cytotoxicity and cytoprotection of ursodeoxycholic acid", Biochim Biophys Acta, 1788, pp.507~513 (2009)
35. Dial EJ, "Importance of biliary excretion of indomethacin in gastrointestinal and hepatic injury", J Gastroenterol Hepatol, 23(8 Pt 2), pp.e384~e389 (2008)
36. Zhou Y, "Effect of indomethacin on bile acid-phospholipid interactions: implication for small intestinal injury induced by nonsteroidal anti-inflammatory drugs", Am J Physiol Gastrointest Liver Physiol, 298, pp.G722~G731 (2010)
37. Graham DY, "Visible small-intestinal mucosal injury in chronic NSAID users", Clin Gastroenterol Hepatol, 3, pp.55~59 (2005)
38. Maiden L, "A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy", Gastroenterology, 128, pp.1172~1178 (2005)
39. Lanas A, "Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications", Gastroenterol Clin North Am, 38, pp.333~352 (2009)
40. Bjarnason I, "Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans", Gastroenterology, 104, pp.1832~1847 (1993)
41. Wallace JL, "Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis", Gastroenterology, 141, pp.1314~1322 (2011)
42. Watanabe T, "Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent", Gut, 57, pp.181~187 (2008)
43. Lichtenberger LM, "Aspirin’s ability to induce intestinal injury in rats is dependent on bile and can be reversed if pre-associated with phosphatidylcholine", J Physiol Pharmacol, 62, pp.491~496 (2011)
44. Lichtenberger LM, "NSAID injury to the gastrointestinal tract: evidence that NSAIDs interact with phospholipids to weaken the hydrophobic surface barrier and induce the formation of unstable pores in membranes", J Pharm Pharmacol, 58, pp.1421~1428 (2006)
45. Zhou Y, "The anti-inflammatory drug indomethacin alters nanoclustering in synthetic and cell plasma membranes", J Biol Chem, 285, pp.35188~35195 (2010)
46. Zhou Y, "The nonsteroidal anti-inflammatory drug indomethacin induces heterogeneity in lipid membranes: potential implication for its diverse biological action", PLoS One, 5, pp.e8811~ (2010)
47. Lichtenberger LM, "Association of phosphatidylcholine and NSAIDs as a novel strategy to reduce gastrointestinal toxicity", Drugs Today (Barc), 45, pp.877~890 (2009)
48. Yamada T, "Bile secretion in rats with indomethacin-induced intestinal inflammation", Am J Physiol, 270(5 Pt 1), pp.G804~G812 (1996)
49. Cryer B, "Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial", Am J Gastroenterol, 106, pp.272~277 (2011)
50. Lichtenberger LM, "Gastrointestinal safety and therapeutic efficacy of parenterally administered phosphatidylcholine-associated indomethacin in rodent model systems", Br J Pharmacol, 157, pp.252~257 (2009)
51. Lichtenberger LM, "Zwitterionic phospholipids enhance aspirin’s therapeutic activity, as demonstrated in rodent model systems", J Pharmacol Exp Ther, 277, pp.1221~1227 (1996)
52. Kurinets A, "Phosphatidylcholine-associated aspirin accelerates healing of gastric ulcers in rats", Dig Dis Sci, 43, pp.786~790 (1998)
53. Lichtenberger LM, "Naproxen-PC: a GI safe and highly effective anti-inflammatory", Inflammopharmacology, 17, pp.1~5 (2009)
54. Billiau A, "Modes of action of Freund’s adjuvants in experimental models of autoimmune diseases", J Leukoc Biol, 70, pp.849~860 (2001)
55. Lichtenberger LM, "Phosphatidylcholine association increases the anti-inflammatory and analgesic activity of ibuprofen in acute and chronic rodent models of joint inflammation: relationship to alterations in bioavailability and cyclooxygenase-inhibitory potency", J Pharmacol Exp Ther, 298, pp.279~287 (2001)
56. Wallace JL, "New pharmacologic therapies in gastrointestinal disease", Gastroenterol Clin North Am, 39, pp.709~720 (2010)
57. Scheiman JM, "Prevention of damage induced by aspirin in the GI tract", Best Pract Res Clin Gastroenterol, 26, pp.153~162 (2012)
58. Darling RL, "The effects of aspirin on gastric mucosal integrity, surface hydrophobicity, and prostaglandin metabolism in cyclooxygenase knockout mice", Gastroenterology, 127, pp.94~104 (2004)
59. Laine L, "Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial", Gastroenterology, 127, pp.395~402 (2004)
60. Lichtenberger LM, "Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin", Br J Pharmacol, 150, pp.913~919 (2007)
61. Mizuno H, "Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice", Gastroenterology, 112, pp.387~397 (1997)
62. Schmassmann A, "Role of the different isoforms of cyclooxygenase and nitric oxide synthase during gastric ulcer healing in cyclooxygenase-1 and -2 knockout mice", Am J Physiol Gastrointest Liver Physiol, 290, pp.G747~G756 (2006)
63. Rahme E, "NSAIDs and risk of lower gastrointestinal bleeding", Lancet, 376, pp.146~148 (2010)
64. Hackelsberger A, "Age and Helicobacter pylori decrease gastric mucosal surface hydrophobicity independently", Gut, 43, pp.465~469 (1998)

관련 논문AI추천